These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 16463403)

  • 1. A Food and Drug Administration primer.
    Simon LS
    Arthritis Rheum; 2006 Feb; 55(1):4-8. PubMed ID: 16463403
    [No Abstract]   [Full Text] [Related]  

  • 2. The special treatment.
    Osborne R
    Nat Biotechnol; 2008 May; 26(5):487-9. PubMed ID: 18464770
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA restructures new product review centers.
    Bouchie A
    Nat Biotechnol; 2002 Oct; 20(10):960. PubMed ID: 12355100
    [No Abstract]   [Full Text] [Related]  

  • 4. Today's FDA.
    Slater EE
    N Engl J Med; 2005 Jan; 352(3):293-7. PubMed ID: 15659733
    [No Abstract]   [Full Text] [Related]  

  • 5. From laboratory to medicine cabinet.
    Caring; 1992 Nov; 11(11):16-20. PubMed ID: 10121248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA not NIH can speed new drugs.
    Miller HI
    Nature; 2011 Apr; 472(7342):169. PubMed ID: 21490657
    [No Abstract]   [Full Text] [Related]  

  • 7. Sweeping changes to Food and Drug Administration and drug safety regulations.
    Cross JT
    Arch Intern Med; 2007 Apr; 167(7):732. PubMed ID: 17420439
    [No Abstract]   [Full Text] [Related]  

  • 8. Avoiding the regulatory capture of the Food and Drug Administration.
    Egilman DS; Presler AH; Valentin CS
    Arch Intern Med; 2007 Apr; 167(7):732-3. PubMed ID: 17420438
    [No Abstract]   [Full Text] [Related]  

  • 9. New office and new leader aim to streamline FDA cancer drug review process.
    Twombly R
    J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036
    [No Abstract]   [Full Text] [Related]  

  • 10. Generic drug approval: a US perspective.
    Nagori BP; Mathur V; Garg S
    Curr Med Res Opin; 2011 Mar; 27(3):541-5. PubMed ID: 21219120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remarks of the Lead Deputy Commissioner of the Food and Drug Administration.
    Friedman MA
    Food Drug Law J; 1998; 53(1):19-23. PubMed ID: 11795333
    [No Abstract]   [Full Text] [Related]  

  • 12. What ails the FDA?
    Jenny-Avital ER
    N Engl J Med; 2005 Jun; 352(24):2554-5. PubMed ID: 15962407
    [No Abstract]   [Full Text] [Related]  

  • 13. Effort to privatize drug reviews grows.
    Scott L
    Mod Healthc; 1995 Jun; 25(26):54. PubMed ID: 10143746
    [No Abstract]   [Full Text] [Related]  

  • 14. Perspectives. Approval process a moving target in FDA reform hearings.
    Rhein R
    Faulkner Grays Med Health; 1996 Feb; 50(8):suppl 1-4. PubMed ID: 10154482
    [No Abstract]   [Full Text] [Related]  

  • 15. The drive to reform the FDA gains momentum.
    Gatty B
    Hosp Formul; 1995 Mar; 30(3):178, 177. PubMed ID: 10141250
    [No Abstract]   [Full Text] [Related]  

  • 16. Who would approve new drugs if there were no FDA?
    Gatty B
    Hosp Formul; 1995 Jan; 30(1):58, 57. PubMed ID: 10139726
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug advisory committees. Getting outside advice for close calls.
    Farley D
    FDA Consum; 1995 Mar; 29(2):23-6. PubMed ID: 10172354
    [No Abstract]   [Full Text] [Related]  

  • 18. Changes in FDA drug classification and priority review policy.
    Crawford SY
    Am J Hosp Pharm; 1992 Oct; 49(10):2383, 2386. PubMed ID: 1442812
    [No Abstract]   [Full Text] [Related]  

  • 19. BIO and biogenerics.
    Feldbaum CB
    Nat Biotechnol; 2005 Jan; 23(1):17; discussion 17. PubMed ID: 15637607
    [No Abstract]   [Full Text] [Related]  

  • 20. Looking for solid ground along the Critical Path.
    Ratner M
    Nat Biotechnol; 2006 Aug; 24(8):885-7. PubMed ID: 16900118
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.